2021 Revenues ($USD) : $494,366,000
2021 R&D spend : $132,010,000
2021 Number of Employees : 1,023
Fiscal Year End : 12/31/2020
Key People : Asaf Danziger, CEO; Yoram Palti, founder; William F. Doyle, executive chair; Ely Benaim, chief medical officer; Ashley Cordova, CFO; Wilco Groenhuysen, COO; Frank Leonard, chief development officer; Todd Longsworth, general counsel; Pritesh Shah, chief commercial officer; Uri Weinberg, chief science officer; William Burke, chief human resources officer.

About the company: Headquartered off the French coast in Jersey, Novocure was founded in 2000 by Yoram Palti, a biophysics expert seeking to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Now an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia, Novocure offers its tumor treating fields (TTFields) platform of electric fields designed to disrupt cancer cell division. TTFields are intended principally for use with other standard-of-care cancer treatments. –SW